(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?- What are parents to do as doctors clash with Trump administration over vaccines?
- Craig the beer-ambassador elephant dies aged 54
- Tickets for 'Stranger Things' Season 5 finale, to be shown in movie theaters on New Year's Eve, go on sale today. Here's how you can save your seat.
- Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- Flu surges across U.S. as doctor visits reach highest level since 1997
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- 5 Great Crossover Vehicles For Eco-friendliness In 2024
- Unwind: Four Extraordinary Spa Resorts On the planet
